Drug Profile
SLV 342
Alternative Names: SLV342Latest Information Update: 01 Feb 2013
Price :
$50
*
At a glance
- Originator Genfit; Solvay
- Developer Abbott Laboratories; Genfit
- Class Cardiovascular therapies
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis